SCHEMBL6037074

SCHEMBL6037074

NC1[C@H](n2ccc(=O)[nH]c2=O)O[C@H](CO)[C@H]1O.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2N)c(=O)n1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.67
THRB P10828 1/20 0.67
MTOR P42345 1/20 0.67
MDM2 Q00987 1/20 0.67
NCOA1 Q15788 1/20 0.67
NCOA3 Q9Y6Q9 1/20 0.67
SLC29A1 Q99808 2/20 0.63
SLC28A1 O00337 1/20 0.63
SLC28A2 O43868 1/20 0.63
SLC28A3 Q9HAS3 1/20 0.63
P2RY2 P41231 6/20 0.60
P2RY6 Q15077 2/20 0.54
P2RY4 P51582 3/20 0.52
PDE4D Q08499 1/20 0.49
PDE3A Q14432 1/20 0.49
P2RY12 Q9H244 2/20 0.48
P2RY14 Q15391 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6037075 1.00 LMNA (0.67) LMNATHRBMTORMDM2NCOA1
Cytidine SCHEMBL17371752 0.92 LMNA (0.80) LMNATHRBMTORMDM2NCOA1
Cytidine SCHEMBL600535 0.92 LMNA (0.80) LMNATHRBMTORMDM2NCOA1
SCHEMBL14565251 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL11120331 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL14580391 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL12031031 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL30116 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL21423095 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1
SCHEMBL30115 0.90 LMNA (0.81) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060036087-A1 2'-deoxy-2'-fluoro modified RNA RIBOZYME PHARMACEUTICALS, INC. 2006-02-16 US disclosed
US-6890908-B1 Modified ribozymes MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2005-05-10 US disclosed
US-5817635-A RNA MOLECULES WITH CATALYTIC ACTIVITY MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1998-10-06 US disclosed
US-5698687-A RNA MOLECULE CONTAINING MODIFIED NUCLOSIDE MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1997-12-16 US disclosed
US-5672695-A GENETIC ENGINEERED RNA MOLECULE, ATLEAST ONE MODIFIED NUCLEOSIDE HAVING A HALO, AMINO, MONO OR DISUBSTITUTED AMINO AND AZIDE MODIFIER GROUPS REPLACING HYDROXY GROUP AT 2' POSITION OF DRIBOSE SUGAR; SHOWS CATALYTIC ACTIVITY MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1997-09-30 US disclosed
EP-0552178-B1 MODIFIED RIBOZYMES MAX PLANCK GESELLSCHAFT (DE) 1997-01-02 EP disclosed
EP-0552178-A1 MODIFIED RIBOZYMES. MAX PLANCK GESELLSCHAFT (DE) 1993-07-28 EP disclosed
WO-1992007065-A1 MODIFIED RIBOZYMES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1992-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036087-A1 2'-deoxy-2'-fluoro modified RNA RNGTT, NSUN2, NSUN3 LMNA 4076/4885THRB 3468/4885MTOR 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.